Ifoxetine Explained

Ifoxetine (CGP-15,210-G) is a selective serotonin reuptake inhibitor (SSRI) which was investigated as an antidepressant in the 1980s but was never marketed.[1] [2] [3] Ifoxetine selectively blocks the reuptake of serotonin in the brain supposedly without affecting it in the periphery.[3] Supporting this claim, ifoxetine was found to be efficacious in clinical trials and was very well tolerated, producing almost no physical side effects or other complaints of significant concern.[3]

Notes and References

  1. Burrows GD, McIntyre IM, Judd FK, Norman TR . Clinical effects of serotonin reuptake inhibitors in the treatment of depressive illness . The Journal of Clinical Psychiatry . 49 Suppl . 18–22 . August 1988 . 3045107 .
  2. Waldmeier PC, Maître L, Baumann PA, etal . Ifoxetine, a compound with atypical effects on serotonin uptake . European Journal of Pharmacology . 130 . 1–2 . 1–10 . October 1986 . 2877890 . 10.1016/0014-2999(86)90177-9.
  3. Delini-Stula A, Fischbach R, Gauthier JM, etal . First clinical experience with ifoxetine, a new 5-HT reuptake blocker with particular emphasis on the side-effect profile of the 5-HT-uptake inhibiting drugs . International Clinical Psychopharmacology . 2 . 3 . 201–15 . July 1987 . 3320185 . 10.1097/00004850-198707000-00003.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Ifoxetine".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.